
With Columbia as a model, White House seeks fines in potential deals with Harvard and others
Fines have become a staple of proposed deals in talks with Harvard and other schools, according to the official, who spoke on the condition of anonymity to discuss internal deliberations.
The new strategy was first reported by The Wall Street Journal.
Federal civil rights investigations into schools and universities almost always have been resolved through voluntary settlements, yet they rarely include financial penalties. The Biden administration reached dozens of such deals with universities and none included fines.
Columbia's settlement with the Trump administration included a $200 million fine in exchange for regaining access to federal funding and closing investigations accusing Columbia of tolerating harassment of Jewish students and employees.
The agreement announced Wednesday also orders Columbia to ensure its admissions and hiring decisions are 'merit-based' with no consideration of race, to hire more Jewish studies faculty, and to reduce the university's reliance on international students, among other changes. It places Columbia under the watch of an independent monitor and requires regular disclosures to the government.
The agreement deal includes a clause forbidding the government from directly dictating decisions on hiring, admissions or academics. Columbia leaders said it preserves the university's autonomy while restoring the flow of federal money.
The Trump administration is investigating dozens of universities over allegations that they failed to address campus antisemitism amid the Israel-Hamas war, and several institutions have faced federal funding freezes, like those at Columbia and Harvard.
The federal government has frozen more than $1 billion at Cornell University, along with $790 million at Northwestern University.
In announcing the Columbia settlement, administration officials described it as a template for other universities. Education Secretary Linda McMahon called it a 'roadmap' for colleges looking to regain public trust, saying it would 'ripple across the higher education sector and change the course of campus culture for years to come.'
As Trump departed the White House on Friday, he told reporters that Harvard 'wants to settle' but that Columbia 'handled it better.' The president said he's optimistic his administration will prevail in Harvard's legal challenge — at least on appeal — and he suggested Harvard may never regain the level of federal funding it received in the past.
'The bottom line is we're not going to give any more money to Harvard,' he said. 'We want to spread the wealth.'
___
The Associated Press' education coverage receives financial support from multiple private foundations. AP is solely responsible for all content. Find AP's standards for working with philanthropies, a list of supporters and funded coverage areas at AP.org.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Daily Mail
28 minutes ago
- Daily Mail
Beach City abandons 10,000 homes for F1-style race track development
Locals in a popular New Jersey beach city are enraged after it ditched plans to build 10,000 new homes for a 'dumb' and 'desperate' $3.4 billion F1-style racetrack. Atlantic City government officials have moved forward with the redevelopment of Bader Field, a shuttered airport about an hour outside of Philadelphia, after plans for the new racetrack were officially approved on July 16. The idea to take over the abandoned city-owned airport, which shut down in 2006, first started in 2022 when Bart Blatstein, the CEO of Tower Investments, Inc. and owner of Showboat Atlantic City, said his company and Atlantic City would collaborate to create a massive residential community. The proposed $3 billion development, dubbed 'Casa Mar,' was set to be built on 140 acres with 10,000 residential units, 20 acres of trails, amenities and parks and 400,000 square-feet of retail and office space - but that plan has since been wiped. Instead, a 2.5-mile racetrack, headed by real estate development company Deem Enterprises, will take its place. The massive raceway, said to be a 'game changer' by Atlantic City Mayor Marty Small Sr. (pictured), is expected to take six to nine years to complete. It will be surrounded by retail businesses and condominiums in the community that is home to beaches, a bustling boardwalk and casinos. 'We're more confident than ever that we have the funds, Small Sr., an Atlantic City native who has been in office since 2019, told NJ Advance Media. [DEEM] has been vetted, and just getting a $3.4-plus billion project on the ratable base is a complete game changer.' While the mayor, who was embroiled in a child abuse scandal involving his wife and daughter last year, and other government officials are thrilled about the new plan, Atlantic City locals are not happy with it. 'Atlantic City leadership is so desperate that they will support any development offer no matter how stupid it is,' a Facebook user wrote. Another said: 'What a joke! Want to really do something with the land? Dig canals and sell off lots and watch the ratepayers flood in!' 'Building that into a racetrack has to be the dumbest idea in the world,' someone else posted. Blatstein told the outlet three years ago that he saw room for growth in the beach city after realizing that other Garden State beach towns have booming populations compared to Atlantic City. 'So what really is needed here is a new plan, a new way of living, a new opportunity for people to come to Atlantic City,' Blatstein said. DEEM Enterprises, a Los Angeles and Atlantic City-based company, first announced the proposal in February of that year. The company has a tentative deal with the city to sell the vacant airfield for $100 million in exchange the real estate developer would donate $15 million for a community center. 'We don't have a recreation center of our town,' Small Sr. explained. 'We use the schools and different things like that.' Daily Mail contacted Mayor Small Sr. and DEEM Enterprises for comment.


The Independent
30 minutes ago
- The Independent
Weight-loss jab Wegovy sees another prescription boost after ban on copycats
Novo Nordisk's weight loss drug, Wegovy, is experiencing a surge in new prescriptions following a US ban on its copycat versions, though analysts caution that more substantial growth is needed to reassure investors. Since the US Food and Drug Administration (FDA) implemented a ban on 'compounded' versions of Wegovy on 22 May, new prescriptions for the drug have risen by approximately 33 per cent. This culminated in 181,200 new prescriptions in the week ending 18 July, according to IQVIA data shared with Reuters by industry analysts. The overall increase in Wegovy prescriptions is also narrowing the market lead held by Eli Lilly and Co's rival drug, Zepbound. While Zepbound prescriptions outpaced Wegovy by nearly 175,000 in the US during the week ending 23 May, this gap had reduced to around 133,000 by 18 July. Early signs of a shift come at a critical juncture for Novo. After Wegovy's initial stunning success, investor confidence was rattled when Zepbound and compounders started to slow the drug's growth. And then in May, the Danish company cut its full-year sales and earnings forecasts and announced the surprise exit of Chief Executive Lars Fruergaard Jorgensen, citing market challenges and a stock price nearly 60% below its 2024 peak. Jorgensen said at the time he expected the FDA compounding ban to lift sales in the second half of this year. Investors are keen to hear whether that is still likely when the company reports quarterly earnings on August 6. That leaves the drugmaker in what Barclays analyst Emily Field called a "show me" phase - no longer buoyed by optimism about a turnaround but under pressure to deliver. She has an "overweight" rating on Novo's shares. "We thought this trajectory change (in new prescriptions) would get the shares moving, but not so far," Berenberg analyst Kerry Holford told Reuters. "I suspect investors are now waiting for the (second quarter) update - will they/won't they trim guidance range? I think they will trim the top." Berenberg has a "hold" rating on Novo. Novo did not respond to a request for comment. Investors and analysts note that the IQVIA prescription data is incomplete, because it does not capture sales of Wegovy through the company's direct-to-consumer platform, NovoCare, launched in March. They estimate the channel is still a small slice of overall Wegovy volume. "We would hope to see strong growth from the NovoCare channel but are cognizant that this may come at initially lower prices" due to discount offers, said Marcus Morris-Eyton, a portfolio manager at Alliance Bernstein, whose fund holds Novo shares. "Sentiment towards Novo Nordisk is currently exceptionally weak, but given low expectations, the low valuation and hopefully accelerating prescription data in (the second half of 2025) we believe the market is underestimating Novo's long term growth potential," he said. Booming sales of Wegovy catapulted Novo to become Europe's most valuable listed company, peaking in June 2024 at about 615 billion euros, after the weekly injection became the first highly-effective obesity treatment approved in the U.S. in 2021. But supply disruptions and gaps in health insurance coverage for Wegovy helped fuel the market for cheaper compounded - or copycat - versions, which are allowed under U.S. law when drugs are in shortage. Investor sentiment on Novo soured after the company lost ground to U.S. rival Eli Lilly, which launched Zepbound in late 2023. Capturing more of the patients who had turned to compounded drugs is key to meeting targets. The FDA determined that Wegovy was no longer in shortage in February, leading to the ban on compounded versions. Novo has rolled out new tactics to bring patients back, including a limited-time discount for one month's supply, and secured better coverage from insurer CVS Health. Analysts at Berenberg and UBS are sceptical these moves will provide enough momentum and expect that Novo will reduce or narrow its full-year guidance ranges, according to research notes. TD Cowen said the outcome was hard to predict due to limited visibility on NovoCare. Bank of America and Guggenheim said they did not expect another guidance cut and Barclays said it was unlikely. ($1 = 0.8513 euros)


The Independent
30 minutes ago
- The Independent
JD Vance hits the road to sell Trump's ‘Big, Beautiful Bill'
Vice President JD Vance will visit his home state of Ohio on Monday to continue promoting the GOP's sweeping tax-and-border bill. His office confirmed he will be in Canton, Ohio, to discuss the bill's 'benefits for hardworking American families and businesses'. While his aides offered little detail in advance about the visit, NBC News reported that his remarks will take place at a steel plant in Canton, located about 60 miles south of Cleveland. The visit marks Vance's second trip this month to sell the legislative package, filled with a hodgepodge of conservative priorities that Republicans have dubbed the 'One Big, Beautiful Bill' as the vice president becomes its chief promoter on the road. In West Pittston, Pennsylvania, Vance told attendees at an industrial machine shop that they should be able to keep more of their pay in their pockets, highlighting the law's new tax deductions on overtime. Vance also discussed a new children's savings program called Trump Accounts and how the new law promotes energy extraction, while decrying Democrats for opposing the bill that keeps the current tax rates, which would have otherwise expired later this year. The legislation cleared the GOP-controlled Congress by the narrowest of margins, with Vance breaking a tie vote in the Senate for the package that also sets aside hundreds of billions of dollars for Trump's immigration agenda while slashing Medicaid and food stamps. The vice president is also stepping up his public relations blitz on the bill as the White House tries to deflect attention away from the growing controversy over Jeffrey Epstein. The disgraced financier killed himself, authorities say, in a New York jail cell in 2019 as he awaited trial on sex trafficking charges. Trump and his top allies stoked conspiracy theories about Epstein's death before Trump returned to the White House and are now reckoning with the consequences of a Justice Department announcement earlier this month that Epstein did indeed die by suicide and that no further documents about the case would be released. Questions about the case continued to dog Trump in Scotland, where he on Sunday announced a framework trade deal with the European Union. Asked about the timing of the trade announcement and the Epstein case and whether it was correlated, Trump responded: 'You've got to be kidding with that.' 'No, had nothing to do with it,' Trump told the reporter. 'Only you would think that.' The White House sees the new law as a clear political boon, sending Vance to promote it in swing congressional districts that will determine whether Republicans retain their House majority next year. The northeastern Pennsylvania stop is in the district represented by Republican Rep. Rob Bresnahan, a first-term lawmaker who knocked off a six-time Democratic incumbent last fall. On Monday, Vance will be in the district of Democratic Rep. Emilia Sykes, who is a top target for the National Republican Congressional Committee this cycle. Polls before the bill's passage showed that it largely remained unpopular, although the public approves of some individual provisions, such as increasing the child tax credit and allowing workers to deduct more of their tips on taxes.